Medicines Company buys ProFibrix following positive PhIII
This article was originally published in Scrip
Executive Summary
ProFibrix's lead biologic Fibrocaps – a mixture of two blood clotting proteins – has met the primary endpoint in the Phase III FINISH-3 trial. The Medicines Company (MedCo) agreed in June 2013 to acquire ProFibrix if FINISH-3 was successful.